Glucokinase (GCK) catalyzes the rate-limiting step of glucose catabolism in the pancreas, where it functions as the body's principal glucose sensor. GCK dysfunction leads to several potentially fatal diseases including maturity-onset diabetes of the young type II (MODY-II) and persistent hypoglycemic hyperinsulinemia of infancy (PHHI). GCK maintains glucose homeostasis by displaying a sigmoidal kinetic response to increasing blood glucose levels. This positive cooperativity is unique because the enzyme functions exclusively as a monomer and possesses only a single glucose binding site. Despite nearly a half century of research, the mechanistic basis for GCK's homotropic allostery remains unresolved. Here we explain GCK cooperativity in terms of large-scale, glucose-mediated disorder-order transitions using 17 isotopically labeled isoleucine methyl groups and three tryptophan side chains as sensitive nuclear magnetic resonance (NMR) probes. We find that the small domain of unliganded GCK is intrinsically disordered and samples a broad conformational ensemble. We also demonstrate that small-molecule diabetes therapeutic agents and hyperinsulinemia-associated GCK mutations share a strikingly similar activation mechanism, characterized by a population shift toward a more narrow, well-ordered ensemble resembling the glucose-bound conformation. Our results support a model in which GCK generates its cooperative kinetic response at low glucose concentrations by using a millisecond disorder-order cycle of the small domain as a ''time-delay loop,'' which is bypassed at high glucose concentrations, providing a unique mechanism to allosterically regulate the activity of human GCK under physiological conditions.
Introduction
Human pancreatic glucokinase (GCK) is the body's principal glucose sensor [1] . GCK is a 52 kDa monomeric enzyme that catalyzes the formation of glucose-6-phosphate from glucose and ATP [2] . This chemical transformation represents the rate-limiting step of glucose catabolism in the pancreas, allowing GCK activity to regulate the rate at which insulin is secreted from b-cells [3] [4] [5] . The importance of this enzyme in maintaining glucose homeostasis is emphasized by several disease states associated with GCK dysfunction. Loss-of-function mutations, of which more than 600 have been described, cause either maturity onset diabetes of the young type II (MODY-II) or permanent neonatal diabetes mellitus (PNDM) [6] . A small number of gain-of-function mutations have also been identified in patients with the potentially fatal disease, persistent hypoglycemic hyperinsulinemia of infancy (PHHI) [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Functional characterization indicates that most PHHIassociated variant enzymes display a reduced level of positive cooperativity toward glucose. Interestingly, many of the PHHIassociated substitutions co-localize to a common region of the GCK scaffold that is distant from the active site [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . In recent years, pharmaceutical research has directed significant efforts toward developing synthetic allosteric activators that target GCK as a strategy to lower blood glucose levels in type 2 diabetic patients [20] . At least one GCK activator has advanced to phase II clinical trials as an antidiabetic agent, yet the functional role and molecular basis of action of such molecules is poorly understood [21] . Similarly, the mechanism of hyperactivity associated with PHHI-linked GCK variants is unclear.
GCK's unique kinetic features are responsible for its physiological role in maintaining glucose homeostasis. The steady-state velocity shows a sigmoidal dependence upon glucose concentration, with a Hill coefficient of 1.7 [2] . This positive cooperativity enables GCK to sensitively respond to small perturbations in blood glucose concentrations, whereby the midpoint of this steadystate response, K 0.5 , approximates physiological blood sugar levels (4-10 mM). The kinetic cooperativity of GCK is mechanistically distinct from other modes of allostery, which involve polypeptide oligomerization or require multiple ligand binding sites [22] [23] [24] [25] . Two theoretical mechanisms-the ligand-induced slow transition (LIST) and mnemonic models-have been put forth to explain kinetic cooperativity in monomeric GCK [26, 27] . In both models, cooperativity is postulated to result from slow conformational transitions that accompany glucose binding and/or product release. The models differ, however, in the relative degree of conformational heterogeneity displayed by the enzyme at various stages along the reaction coordinate. According to the LIST mechanism, two separate catalytic cycles are possible resulting from two distinct conformations of the enzyme. In contrast, the mnemonic model postulates a single catalytically active enzyme conformation with the ability to ''remember'' its active state for only a short period of time following turnover. Although data have accumulated over the years in support of each mechanism, a consensus has yet to be reached [28] [29] [30] [31] [32] [33] .
X-ray crystallographic structures reveal that GCK adopts a prototypic hexokinase fold, consisting of a small and large domain separated by a variable opening angle dependent upon substrate association ( Figure 1A ) [28] . The kinetic mechanism of GCK is strictly ordered [2] , with glucose binding first, accompanied by a large structural rearrangement from an open to a closed structure ( Figure 1B) . Binding of ATP does not induce significant additional changes to the structure of the glucose-bound state ( Figure 1C ) [34] . The crystal structures also identify a common binding site for synthetic GCK activators at a location within the small domain that is approximately 20 Å removed from the glucose binding site.
Differences observed between available crystal structures demonstrate the ability of GCK to sample discrete conformations, but they do not explain the dynamic basis of allosteric regulation as set forth in the LIST and mnemonic models [28, 29, [34] [35] [36] [37] [38] . Herein, we describe the results of the first investigation of the functional dynamics of GCK at atomic detail by high-resolution NMR of specifically labeled side chains. We characterize the conformational dynamics of the wild-type enzyme as it progresses along the reaction coordinate and explain the molecular mechanism of kinetic cooperativity. We also uncover the molecular basis of activation observed in PHHI-associated variants or when a synthetic activator associates with the enzyme. Our findings suggest a model for GCK cooperativity involving a slow disorder-order cycle of an intrinsically disordered domain that is operational under low glucose concentrations but that is bypassed at elevated glucose concentrations.
Results and Discussion
The Small Domain of GCK Is Intrinsically Disordered
The large size and dynamic nature of GCK, combined with the poor spectral dispersion even upon perdeuteration, prevented the use of traditional NMR approaches for backbone resonance assignment and structural analysis [32] . Instead, we focused on selected side chains only, a strategy that has proven effective for studies of other challenging protein systems and large complexes [39, 40] . For this purpose, we introduced 13 C spin probes in the Cd1 methyl groups of 17 isoleucine side chains and 15 N spin probes at the Ne sites of three tryptophan side chains [39] [40] [41] . The labeled residues are quite uniformly distributed throughout the enzyme's structure. The large domain contains one Trp and 10 Ile residues, while two Trp and seven Ile residues reside in the small domain (red and yellow spheres in Figure 1A -C). Together these probes permit the study of internal dynamics throughout the protein. Importantly, the methyl resonances can retain narrow line widths even in high-molecular weight proteins through the methyl-TROSY effect manifested in the 2D 1 H-13 C HMQC experiment used here [39, 40] . Site-specific assignment of Ile and Trp resonances was achieved by single-site substitutions with Val and Phe, respectively, followed by the recording of 2D 1 H-13 C HMQC and 1 H- 15 N HSQC spectra to identify missing cross-peaks ( Figure  S1 ).
To achieve a global portrait of the enzyme's structure and dynamics prior to glucose association, we collected 1 H-13 C HMQC spectra of 13 CH 3 -Ile labeled GCK. The 1 H- 13 C HMQC of unliganded GCK displays a high degree of cross-peak overlap and heterogeneous peak intensities ( Figures 1D and S2 ). This behavior is consistent with previously reported, unassigned 1 H-15 N TROSY spectra of GCK specifically labeled on Ile backbone atoms [32] . Nine Ile residues located in the large domain and two Ile side chains situated in the small domain are observable in unliganded GCK. The 2D 1 H-15 N HSQC spectrum of unliganded 15 N-Trp labeled GCK reveals only a single cross-peak. Mutagenesis demonstrated that this cross-peak is dominated by contributions from W167 ( Figure S3) . Notably, the only small domain residues observable in the unliganded spectra-I159, I163, and W167-all reside in a loop that is absent in the X-ray structure of unliganded GCK. The sharp cross-peaks originating from these three residues, along with the nearly degenerate chemical shifts of the Ile 159 and 163, reflect the presence of extensive rapid motional averaging and indicate that this loop is disordered, both in the crystal and in solution ( Figure S4 ) [42, 43] .
To investigate whether the absence of the resonances of five isoleucines belonging to the small domain results from motions of these side chains occurring on the intermediate exchange regime (ms -ms time scale), we collected 1 H- 13 C HMQC spectra of unliganded GCK at variable temperatures. Across a range of temperatures (283-313 K) compatible with retention of enzyme activity, no additional cross-peaks were observed that could be attributed to the five missing small domain isoleucine side chains ( Figure S5 ). We tested whether the five missing isoleucine cross-
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peaks might reside in the intrinsically disordered side chain region of the 1 H-13 C HMQC spectrum, underneath the sharp, intense peaks of I159 and I163, by constructing a variant in which I159 and I163 were replaced with leucines. These substitutions had a minimal impact upon the kinetic properties of the enzyme (Table  S1) ; however, the removal of I159 and I163 did not eliminate all peak intensity in the region of the spectrum where disordered side chains are expected. Therefore, residual intensity observed in the I159L-I163L double variant could stem from some of the remaining isoleucine side chains in the small domain ( Figure  S6 ). Together these results show that the majority of the isoleucines of the small domain are subject to conformational exchange with an exchange rate k ex that fulfills the NMR coalescence condition k ex <2.2Dv, where Dv is the chemical shift change between conformational substates of unliganded GCK. At least two isoleucines, I159 and I163, remain fully disordered in the unliganded form of GCK.
Glucose Association Induces Ordering of the Small Domain
Upon addition of glucose, the intensity of the intrinsically disordered region of the 1 H- 13 C HMQC spectrum decreases and new cross-peaks originating from I110, I126, I130, I189, and I211 become clearly visible (blue peaks in Figure 1E ). In contrast, residues in the large domain are much less affected by glucose binding (gray peaks). In the presence of glucose, the cross-peaks of I159 and I163 dramatically increase their line widths and shift to new positions ( Figures 1E and S2 ), reflecting the formation of the 151-179 b-hairpin, a well-defined structural element in the crystal structure 1V4S [28] . In the Figure 1D (for more details, see Figure S4 ). doi:10.1371/journal.pbio.1001452.g001 the binary complex perturbs the spectrum only slightly, indicating that AMP-PNP weakly impacts the structure and dynamics of the binary complex ( Figure 1F ).
Molecular Basis of Activation for PHHI-Associated Substitutions and Therapeutic Agents
Although PHHI is usually associated with single amino acid replacements, we employed our previously identified hyperactive quadruple variant to fully characterize the structural and functional impacts of activating mutations [44] . This hyperactive variant contains a redesigned a13-helix with sequence ALIAAAV. Similar to other activating PHHI-linked variants, the a13-helix variant displays a decreased glucose K 0.5 value, a reduced level of cooperativity, and an increased equilibrium affinity for glucose compared to wild-type GCK [44] . Specifically, the glucose K D value of the a13-helix variant is 50 mM, a value similar to glucose K m values of the noncooperative GCK isozymes, hexokinases I-III. In contrast to wild-type GCK, the Table S1 ). 2D 1 H- 13 C HMQC spectra of (C) unliganded GCK, (D) activatorbound complex, and (E) unliganded a13-helix variant, specifically labeled with Ile 13 C(d1) methyl groups. 2D 1 H-15 N HSQC spectra of (F) unliganded GCK, (G) glucose-bound complex, and (H) unliganded a13-helix variant, with Trp- 15 Ne cross-peaks assigned by black labels. The yellow box highlights the position of the W167 cross-peak. The asterisk indicates that W167 is the main contributor to the intensity of the unliganded cross-peak (for more details, see Figure S3 ). doi:10.1371/journal.pbio.1001452.g002 unliganded a13-helix variant displays cross-peaks originating from Ile residues in both the small and large domains ( Figure 2E ). Under saturating glucose conditions, the a13-helix variant exhibits a spectrum that closely resembles the wild-type glucose-bound spectrum ( Figure S7 ). These spectral characteristics are not specific to the hyperactive a13 variant, as similar effects were observed with the single-site activating variant, S64P ( Figure S8B ). In general, the 1 H- 13 C HMQC spectra of activated variants reveal varying degrees of structural stabilization relative to the wild-type enzyme. We observed a correlation between increases in glucose affinity caused by individual activating GCK variants, a systematic sharpening of cross-peaks, and the appearance of a larger number of resolved cross-peaks in the 1 H-13 C HMQC spectra in their unliganded state ( Figure S8 ). These data demonstrate that activating PHHI-associated substitutions alter enzyme dynamics and promote a conformational ensemble that more closely resembles the glucose-bound state.
Binding of the allosteric activator, which reduces the glucose K 0.5 value and eliminates cooperativity, induces changes in the 2D 1 H- 13 C HMQC spectrum similar to that produced by activating variants (Figure 2 ). Well-dispersed cross-peaks originating from Ile residues in both the large and small domain are observed in the presence of the activator. The only differences between the NMR spectra of glucose-bound GCK in the absence and presence of the activator arise from residues near the activator binding site, such as I211 ( Figure S9 ), suggesting local perturbations only. From these data, we conclude that allosteric activators stabilize the small domain and alter GCK dynamics. Our results also demonstrate that small-molecule-mediated GCK activation does not require prior formation of the binary GCK-glucose complex, a finding that could have important therapeutic implications. Figure 2E and H. Notably, the chemical shift of W167 in the unliganded a13-helix variant is identical to that observed in the wild-type GCK-glucose complex ( Figure 2G and H), indicating that the loop conformation adopted by the variant is similar to that produced upon glucose binding. The crystal structure reveals a possible mode of communication between the activator, the a13-helix, and the 151-179 loop (Figure 2A ) [28] . One face of the activator binding site is comprised of the a13-helix residues V452, V455, and A456, and two of these residues, V452 and A456, interact with the loop residue I159. In the presence of the activator, or when an activating substitution is introduced into the a13-helix, the interactions between I159, V452, and A456 are stabilized. In turn, this stabilization is relayed to the glucose binding site via two additional loop residues, T168 and K169, which form hydrogen bonds with the O1 and O6 atoms of bound glucose. Structural organization of either the a13-helix or the 151-179 loop can be achieved by glucose binding, activator association, or a hyperactive substitution.
Our Data Reveal a Universal Mechanism of GCK Activation
PHHI variants or the allosteric activator promote a population shift toward a more structured state, which involves a major reorganization of the small domain. This effect, which is evidenced by increased spectral dispersion and loss of line broadening compared to the unliganded wild-type enzyme, abrogates kinetic cooperativity. The differential glucose binding affinities of wildtype GCK and the a13-helix variant (K D = 5 mM and 50 mM, respectively) suggest that a substantial thermodynamic barrier separates the closed GCK conformation from the unliganded state. In the wild-type enzyme, this barrier is overcome by glucose binding, which triggers the disorder-order transition. In an activated variant, or in the presence of a synthetic activator, the small domain is stabilized, which decreases the free energy penalty of the conformational change and allows glucose binding energy to manifest itself in the form of a lower K D value. The differential glucose binding affinities of wild-type and activated GCK also suggest that the high-affinity conformation represents #1% of the total unliganded ensemble.
A Refined Model for GCK Cooperativity
The experimental data presented here provide direct evidence that the small domain of GCK is highly dynamic in the absence of ligand. Some evidence of GCK structural plasticity has emerged from X-ray structures determined in the presence and absence of various ligands; however, since crystal structures represent highresolution snapshots of protein states, they neither reveal timescale information nor how different states are dynamically related to each other. Optical spectroscopy, on the other hand, provides time-scale information at single sites without reporting on local structure. Indeed, the application of transient state fluorescence spectroscopy to GCK revealed the existence of glucose-induced structural rearrangements that span multiple time scales, but these studies failed to provide a unified, structure-based mechanism of GCK cooperativity [45] [46] [47] [48] . Here we used all native Ile and Trp side chains to probe the structural-dynamic behavior of GCK at 20 different sites distributed throughout the protein. These data, obtained in solution under physiological conditions in the absence and presence of glucose and activator, provide temporal information for wild-type GCK and its variants with high spatial resolution. Based on this new type of information, we propose a refined model for allostery in monomeric GCK.
The model that emerges from our data demonstrates that GCK cooperativity may result from dynamic structural modulations of the intrinsically disordered small domain. In the absence of ligand, the enzyme exists as an ensemble of conformations, which interconvert on a millisecond time scale that coincides with enzyme turnover (k cat ,60 s 21 ) (Figure 3 ). Upon glucose association the small domain becomes ordered, as reflected in the sharpening of the NMR resonances and the increase of chemical shift dispersion of Ile residues. After formation of the GCKglucose binary complex, ATP binds and catalysis proceeds with little additional reorganization. Following product release, ordered unliganded GCK persists until, on the millisecond time scale, the small domain undergoes an order-disorder transition, allowing access to a ''time delay loop.'' Under low glucose concentrations, the delay loop is operational, leading to slow turnover and kinetic cooperativity (Figure 3, red) . Under high glucose concentrations, or when GCK is activated, the delay loop is effectively bypassed, turnover is fast, and cooperativity is eliminated (Figure 3, green) .
The putative involvement of slow conformational changes in the generation of kinetic cooperativity in enzymes has long been appreciated [49] . In the case of GCK, the generation of a sigmoidal steady-state response, which is key to this enzyme's sensitivity to oscillating physiological glucose levels, requires a time delay slower than 1/k cat . The absence of resonances from Ile residues located in the small domain prevents quantitative analysis of the underlying rate constants associated with the disorder-order transition. However, typical Ile and Trp side-chain chemical shift ranges point to a rate constant k ex between 5 s 21 and 100 s 21 in order to explain the disappearance of the cross-peaks from the small domain by coalescence. This disorder-order transition rate satisfies the conditions needed to account for the existence of kinetic cooperativity in GCK [26, 27] . Protein structural organization occurring in the millisecond time regime is not uncommon [50] , and here this phenomenon appears to contribute to the generation of GCK cooperativity. As with other intrinsically disordered proteins [51, 52] , it is possible that the dynamic nature of the small domain also plays a role for the emergence of new functional attributes, including regulation of GCK activity by multiple interacting partners [53] [54] [55] and posttranslational events [56, 57] .
Materials and Methods

Protein Expression and Purification
Recombinant human pancreatic GCK was produced as an Nterminal hexa-histidine-tagged polypeptide in Escherichia coli strain BL21(DE3). Bacterial cultures were inoculated to an initial OD 600 nm of 0.06 and were grown at 37uC in minimal medium supplemented with ampicillin (150 mg/mL), thiamine hydrochloride (25 mg/mL), (1 mM), and glycerol (1%) (w/v). When the OD 600 nm reached 0.85, IPTG (1 mM) was added to induce gene expression and growth was continued for 12 h. The specific incorporation of 15 N and 13 C labels in the Trp and Ile residues, respectively, was achieved following the protocols by Muchmore et al. [41] and Tugarinov et al. [39] . Cells were harvested by centrifugation at 8,000 g, and 5 g of wet cell pellet was resuspended in 17 mL of buffer A containing HEPES (50 mM, pH 7.6), KCl (50 mM), imidazole (40 mM), dithiothreitol (10 mM), and glycerol (25% w/ v). Cells were lysed using a French Press and subjected to centrifugation at 25,000 g at 4uC for 1 h. The supernatant was immediately loaded onto a 5 ml HisTrap Fast Flow Affinity Column (GE Healthcare) previously equilibrated in buffer A. Following loading, the column was washed with 10 column volumes of buffer A followed by 5 columns of buffer A containing 65 mM imidazole. GCK was eluted with buffer A containing 250 mM imidazole, and the enzyme was dialyzed at 4uC against 1L of potassium phosphate buffer (25 mM, pH 8), containing KCl (25 mM) and dithiothreitol (10 mM). GCK was then concentrated to ,600 mM using an Amicon centrifugal concentrator (MWCO = 10,000). column was run at a flow rate of 0.12 mL/min, and fractions that contained the highest A 280 nm readings were pooled and used immediately in the NMR experiments.
Site-Directed Mutagenesis
Site-directed mutagenesis was performed using the QuikChange protocol (Stratagene). Mutagenesis reactions contained human glk template DNA (400 ng), Pfu Turbo enzyme (2.5 units), cloned Pfu Turbo reaction buffer (16) , and mutagenic primers (125 ng).
Enzyme Assays
GCK activity was measured spectrophotometrically at 340 nm by coupling the production of ADP to the oxidation of NADH via the combined action of pyruvate kinase and lactate dehydrogenase. Assays were conducted at 25uC in reaction mixtures containing HEPES (250 mM, pH 7.6), KCl (50 mM), NADH (0.25 mM), dithiothreitol (10 mM), pyruvate kinase (15 units), lactate dehydrogenase (15 units), ATP (0.1-50 mM), MgCl 2 (1.1-51 mM), and glucose (0.05-100 mM). Data were fitted to the Hill equation or the Michaelis-Menten equation depending on the substrate under investigation. Assays were initiated by the addition of ATP and were conducted in duplicate for each substrate concentration. The kinetic constants reported are the average of data obtained from at least two independent preparations of enzyme. Assays were conducted before and after NMR measurements to verify retention of enzyme activity during the time course of the experiment.
NMR Data Collection, Processing, and Resonance Assignment
All NMR data were collected with a Bruker Avance III spectrometer operating at 800 MHz proton field and equipped with a TCI cryogenic probe. The GCK NMR samples were prepared in potassium phosphate buffer (25 mM, pH 8.0), containing KCl (25 mM), DTT (10 mM), deuterated glycerol (5% v/v), and D 2 O (10% v/v). For all experiments of glucosebound GCK, glucose was added to a total concentration of 200 mM.
1 H- 13 C HMQC experiments were recorded as matrices of 20486390 (in Figure 1) or 20486256 (in Figure 2) complex data points. Unless otherwise stated, 1 H-15 N HSQC experiments were recorded as matrices of 20486128 complex data points. All spectra were apodized with a cosine function in each dimension prior to zero-filling. NMR data processing and spectral analyses were performed with NMRPipe [58] and the CCPN-Analysis software [59] . As a control, the enzymatic activity of GCK was measured before and after each NMR experiment.
Site-specific assignments of Ile and Trp resonances were mainly achieved by single-site substitution with Val/Leu and Phe, respectively, followed by the recording of 2D N HSQC spectra to identify missing cross-peaks ( Figure S7 ). Assignments of Ile residues in the a13-helix variant could be directly transferred from their wild-type assignments due to identical peak positions, except for I159 and I163, which were assigned by sitedirected mutagenesis. Ile residues in the GCK-activator complex were assigned based on identical cross-peak positions with respect to the wild-type spectrum. Assignments for W99, W167, and W257 in wild-type GCK and for W167 in the a13-helix variant were performed by individually replacing Trp by Phe. Figure S1 Illustration of the assignment procedure for Ile crosspeaks of GCK. The spectrum of wild-type GCK in the glucosebound state (black) is superimposed on the spectrum of the I351V variant (red). The disappearance of the cross-peak due to I351 in the mutant is followed by a small chemical shift change of I348 due to their close spatial proximity. H- 13 C HMQC with the 400 mM wild-type GCK (blue) in the unliganded (A) and glucose-bound form (B). In unliganded GCK (A, blue spectrum) the intensity of the intrinsically disordered side-chain region is dominated by I159 and I163. Substitution of these isoleucine residues with leucine revealed the existence of residual intensity in this region attributable to some or all of the other isoleucine residues located in the small domain (A, red, spectrum). Addition of saturating glucose to the variant lacking reporters in the disordered loop region (I159LI163LGCK, B, red spectrum) decreased further the intensity of the intrinsically side chain region compared to the wild-type GCK (B, blue spectrum). The data were recorded as matrices of 1024664 (wild-type) and 10246350 (I159LI163L GCK) complex data points and multiplied by a squared cosine apodization function. 
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